Abstract
Women with polycystic ovary syndrome (PCOS) are characterized by increased cardiometabolic risk. The aim of the current study was to compare the impact of atorvastatin on plasma levels of cardiometabolic risk factors between men whose sisters had either PCOS or were unaffected. The study population consisted of two age-, fat-free mass index-, blood pressure- and plasma lipid-matched groups of men with elevated total and LDL cholesterol levels: 20 brothers of PCOS probands (group 1) and 20 brothers of healthy women (group 2). Both groups were then treated with atorvastatin (40 mg daily) for the following 6 months. At the beginning and at the end of the study, we assessed plasma lipid levels, glucose homeostasis markers and levels of dehydroepiandrosterone sulfate, testosterone, bioavailable testosterone, uric acid, high-sensitivity C-reactive protein (hsCRP), homocysteine, fibrinogen and 25-hydroxyvitamin D. At the beginning of the study, both treatment arms differed in the degree of insulin resistance, calculated bioavailable testosterone, as well as in plasma levels of dehydroepiandrosterone sulfate, uric acid, hsCRP and 25-hydroxyvitamin D. Although atorvastatin reduced total and LDL cholesterol levels, this effect was strong...Continue Reading
References
May 8, 2002·The Journal of Clinical Endocrinology and Metabolism·Richard S LegroAndrea Dunaif
Aug 19, 2003·Drugs·Robert KrysiakZbigniew Herman
Mar 11, 2004·Clinical Endocrinology·R KaushalS S Nussey
May 14, 2005·Human Reproduction·Murat YilmazMetin Arslan
Feb 9, 2006·The Journal of Clinical Endocrinology and Metabolism·Frank GonzálezJohn P Kirwan
Nov 28, 2006·The American Journal of Cardiology·Scott Kinlay, Jesus Egido
Sep 28, 2007·Diabetologia·J-P Baillargeon, A C Carpentier
Nov 10, 2007·The American Journal of Clinical Nutrition·Kilmer S McCully
Mar 12, 2008·Diabetes Care·Susan SamAndrea Dunaif
Apr 25, 2008·Heart Failure Clinics·Nitin MathurDouglas L Mann
Oct 24, 2008·The New England Journal of Medicine·Daniel I FeigRichard J Johnson
Feb 10, 2009·Current Pharmaceutical Design·Qian Zhou, James K Liao
Oct 20, 2009·The Journal of Clinical Endocrinology and Metabolism·Andrea D CovielloAndrea Dunaif
Nov 10, 2009·Journal of the American Board of Family Medicine : JABFM·Teresa KulieSarina Schrager
Oct 25, 2011·Journal of Reproductive Immunology·María Emilia SolanoPetra Clara Arck
Nov 15, 2012·Circulation. Cardiovascular Quality and Outcomes·Lu WangHoward D Sesso
May 15, 2013·The Journal of Biological Chemistry·Yunzi ChenYan Chun Li
Dec 18, 2013·Basic & Clinical Pharmacology & Toxicology·Robert Krysiak, Boguslaw Okopien
Dec 3, 2014·The Medical Clinics of North America·Subbulaxmi Trikudanathan
Jun 3, 2015·Cardiovascular Therapeutics·Robert KrysiakBogusław Okopien
Jan 2, 2016·Pharmacological Reports : PR·Robert KrysiakBogusław Okopień
Oct 25, 2016·Pharmacological Reports : PR·Robert KrysiakBogusław Okopień
Feb 6, 2017·Current Diabetes Reports·Markku Laakso, Johanna Kuusisto
Jun 7, 2017·Advances in Experimental Medicine and Biology·Dilek Yazıcı, Havva Sezer
Jan 15, 2018·Fertility and Sterility·Bulent YilmazBulent Okan Yildiz
Mar 24, 2018·Nature Reviews. Endocrinology·Héctor F Escobar-Morreale
May 31, 2018·Endocrine Connections·Katica Bajuk Studen, Marija Pfeifer
Jul 5, 2018·Archives of Endocrinology and Metabolism·Raiane P CrespoLarissa G Gomes
Jul 22, 2018·Vitamins and Hormones·Carolyn M KlingeRussell A Prough
Feb 8, 2019·Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology·Karthik SubramaniamPreeti Dabadghao
Apr 11, 2019·The Journal of Steroid Biochemistry and Molecular Biology·Brian G Keevil, Jo Adaway
Jul 13, 2019·Human Reproduction·Subramaniam KarthikPreeti Dabadghao
Sep 15, 2019·Trends in Cardiovascular Medicine·Olatokunbo OsibogunErin D Michos
Oct 14, 2019·Reproductive Biology·Beata BanaszewskaRobert Spaczynski